Kalaris Therapeutics, Inc. (KLRS)

NASDAQ: KLRS · Real-Time Price · USD
3.800
-0.050 (-1.30%)
May 9, 2025, 12:28 PM - Market open
-1.30%
Market Cap 71.07M
Revenue (ttm) n/a
Net Income (ttm) -69.17M
Shares Out 18.70M
EPS (ttm) -10.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,693
Open 4.210
Previous Close 3.850
Day's Range 3.800 - 4.210
52-Week Range 4.190 - 24.150
Beta n/a
Analysts Buy
Price Target n/a
Earnings Date May 19, 2025

About KLRS

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 14
Stock Exchange NASDAQ
Ticker Symbol KLRS
Full Company Profile

Financial Performance

Financial Statements

News

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving i...

5 weeks ago - GlobeNewsWire

Kalaris Announces Closing of Merger with AlloVir

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis...

Other symbols: ALVR
7 weeks ago - GlobeNewsWire